Cell-surface markers of prostate cancer 3. PSMA as a target for cancer therapy 4. Antibody-
drug conjugate chemistries 5. Preclinical findings 5.1. PSMA ADC 5.2. MLN2704 5.3 …

Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein
overexpressed in a variety of tumors, especially in nearly all prostate cancers, which makes …

Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that
is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) …

BACKGROUND It is timely and important to develop new treatment modalities for advanced
prostate cancer, because even the newly FDA approved treatments, despite providing …

BACKGROUND Antibody–drug conjugates (ADCs) are an emerging class of cancer
therapies that have demonstrated favorable activity both as single agents and as …

Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …

The prostate-specific membrane antigen (PSMA) represents a valuable antigen for the
generation of antibody–drug conjugates (ADCs), since it is present on the cell surface at all …

Prostate cancer (PC) is a potentially high-risk disease and the most common cancer in
American men. It is a leading cause of cancer-related deaths in men in the US, second only …

Cancer cells can be selectively targeted by identifying and developing antibodies to specific
antigens present on the cancer cell surface. Cytotoxic agents can be conjugated to these …

Simple Summary The prostate-specific membrane antigen (PSMA) protein present in most
prostate cancer cells has emerged as a promising target for the imaging and treatment of …